HDAC11 is a novel drug target in carcinomas

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Histone deacetylase (HDAC) inhibition is a key strategy in cancer therapy.
• Current HDAC inhibitors cause dose-limiting toxicities due to broad target inhibition.
• Selective inhibition of single HDAC family members may overcome these toxicities.

Purpose of the Study:

• To investigate the role of HDAC11, a zinc-dependent HDAC, as a potential cancer drug target.
• To determine if selective inhibition of HDAC11 can induce anti-tumor effects.

Main Methods:

• Analysis of HDAC11 expression in various carcinomas versus healthy tissues.
• Depletion of HDAC11 in cancer cell lines (HCT-116, PC-3, MCF-7, SK-OV-3).
• Expression of a catalytically impaired HDAC11 variant to assess enzymatic activity's role.
• Assessment of metabolic activity and viability in cancer and normal cells.

Main Results:

• HDAC11 is overexpressed in several carcinomas compared to normal tissues.
• HDAC11 depletion leads to cell death and reduced metabolic activity in multiple cancer cell lines.
• Enforced expression of a catalytically impaired HDAC11 mimicked the anti-tumoral effects.
• HDAC11 depletion did not affect metabolic activity or viability in normal cells, suggesting tumor selectivity.

Conclusions:

• HDAC11 plays a critical role in cancer cell survival.
• Selective inhibition of HDAC11 enzymatic activity is a promising strategy for cancer therapy.
• HDAC11 represents a novel and potentially tumor-selective drug target in oncology.